Skip to main content
Top
Published in: Infection 1/2022

01-02-2022 | Pulmonary-Function Tests | Original Paper

Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity

Authors: Dieter Munker, Tobias Veit, Jürgen Barton, Pontus Mertsch, Carlo Mümmler, Andreas Osterman, Elham Khatamzas, Michaela Barnikel, Johannes C. Hellmuth, Maximilian Münchhoff, Julia Walter, Alessandro Ghiani, Stefan Munker, Julien Dinkel, Jürgen Behr, Nikolaus Kneidinger, Katrin Milger

Published in: Infection | Issue 1/2022

Login to get access

Abstract

Objective

Evaluation of pulmonary function impairment after COVID-19 in persistently symptomatic and asymptomatic patients of all disease severities and characterisation of risk factors.

Methods

Patients with confirmed SARS-CoV-2 infection underwent prospective follow-up with pulmonary function testing and blood gas analysis during steady-state cycle exercise 4 months after acute illness. Pulmonary function impairment (PFI) was defined as reduction below 80% predicted of DLCOcSB, TLC, FVC, or FEV1. Clinical data were analyzed to identify risk factors for impaired pulmonary function.

Results

76 patients were included, hereof 35 outpatients with mild disease and 41 patients hospitalized due to COVID-19. Sixteen patients had critical disease requiring mechanical ventilation, 25 patients had moderate–severe disease. After 4 months, 44 patients reported persisting respiratory symptoms. Significant PFI was prevalent in 40 patients (52.6%) occurring among all disease severities. The most common cause for PFI was reduced DLCOcSB (n = 39, 51.3%), followed by reduced TLC and FVC. The severity of PFI was significantly associated with mechanical ventilation (p < 0.001). Further risk factors for DLCO impairment were COPD (p < 0.001), SARS-CoV-2 antibody-Titer (p = 0.014) and in hospitalized patients CT score. A decrease of paO2 > 3 mmHg during cycle exercise occurred in 1/5 of patients after mild disease course.

Conclusion

We characterized pulmonary function impairment in asymptomatic and persistently symptomatic patients of different severity groups of COVID-19 and identified further risk factors associated with persistently decreased pulmonary function. Remarkably, gas exchange abnormalities were revealed upon cycle exercise in some patients with mild disease courses and no preexisting pulmonary condition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRef Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRef
2.
go back to reference Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.CrossRef Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.CrossRef
3.
go back to reference Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRef Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRef
4.
go back to reference Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.CrossRef Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.CrossRef
5.
go back to reference Jakob CEM, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2021;49:63–73.CrossRef Jakob CEM, et al. First results of the “Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS).” Infection. 2021;49:63–73.CrossRef
6.
go back to reference Needham DM, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders’ conference. Crit Care Med. 2012;40:502–9.CrossRef Needham DM, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders’ conference. Crit Care Med. 2012;40:502–9.CrossRef
7.
go back to reference Bieber S, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection. 2021;49:491–500.CrossRef Bieber S, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection. 2021;49:491–500.CrossRef
8.
go back to reference Spiro JE, et al. Secondary tension pneumothorax in a COVID-19 pneumonia patient: a case report. Infection. 2020;48:941–4.CrossRef Spiro JE, et al. Secondary tension pneumothorax in a COVID-19 pneumonia patient: a case report. Infection. 2020;48:941–4.CrossRef
9.
go back to reference Weber S, et al. Severe liver failure during SARS-CoV-2 infection. Gut. 2020;69:1365–7.CrossRef Weber S, et al. Severe liver failure during SARS-CoV-2 infection. Gut. 2020;69:1365–7.CrossRef
11.
go back to reference Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32.CrossRef Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32.CrossRef
12.
go back to reference Quanjer PH, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6:5–40.CrossRef Quanjer PH, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6:5–40.CrossRef
13.
go back to reference Quanjer PH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.CrossRef Quanjer PH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.CrossRef
14.
go back to reference Coates AL, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49:1601526.CrossRef Coates AL, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49:1601526.CrossRef
16.
go back to reference Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef
17.
go back to reference Antonio GE, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228:810–5.CrossRef Antonio GE, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228:810–5.CrossRef
18.
go back to reference Chung M, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:202–7.CrossRef Chung M, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:202–7.CrossRef
19.
go back to reference Dai H, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis. 2020;95:106–12.CrossRef Dai H, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis. 2020;95:106–12.CrossRef
21.
go back to reference Huang Y, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163.CrossRef Huang Y, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163.CrossRef
22.
go back to reference You J, et al. Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J Infect. 2020;81:e150–2.CrossRef You J, et al. Anormal pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients after discharge. J Infect. 2020;81:e150–2.CrossRef
25.
go back to reference Fumagalli A, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. Infection. 2021;49:153–7.CrossRef Fumagalli A, et al. Pulmonary function in patients surviving to COVID-19 pneumonia. Infection. 2021;49:153–7.CrossRef
28.
go back to reference Liu Q, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36:21–3.PubMed Liu Q, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36:21–3.PubMed
29.
go back to reference Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–8.CrossRef Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–8.CrossRef
30.
go back to reference Hui DS, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–9.CrossRef Hui DS, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–9.CrossRef
31.
go back to reference Wells AU, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453–60.CrossRef Wells AU, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453–60.CrossRef
33.
go back to reference Qu J, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2255–8.CrossRef Qu J, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2255–8.CrossRef
34.
go back to reference Zohar T, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183:1508-1519 e12.CrossRef Zohar T, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183:1508-1519 e12.CrossRef
35.
go back to reference Seddiki N, French M. COVID-19 and HIV-associated immune reconstitution inflammatory syndrome: emergence of pathogen-specific immune responses adding fuel to the fire. Front Immunol. 2021;12:649567.CrossRef Seddiki N, French M. COVID-19 and HIV-associated immune reconstitution inflammatory syndrome: emergence of pathogen-specific immune responses adding fuel to the fire. Front Immunol. 2021;12:649567.CrossRef
37.
go back to reference Ostransky D, Blais FX. Postviral bronchial hyperreactivity syndrome: recognizing asthma's great mimic. J Am Osteopath Assoc. 1991;91(5): 465–8, 471–5. Ostransky D, Blais FX. Postviral bronchial hyperreactivity syndrome: recognizing asthma's great mimic. J Am Osteopath Assoc. 1991;91(5): 465–8, 471–5.
38.
go back to reference Folkerts G, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 1998;157:1708–20.CrossRef Folkerts G, et al. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 1998;157:1708–20.CrossRef
39.
go back to reference Lee SC, et al. Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. Sci Rep. 2021;11:3735.CrossRef Lee SC, et al. Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. Sci Rep. 2021;11:3735.CrossRef
40.
41.
go back to reference Zhao YM, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.CrossRef Zhao YM, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.CrossRef
Metadata
Title
Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity
Authors
Dieter Munker
Tobias Veit
Jürgen Barton
Pontus Mertsch
Carlo Mümmler
Andreas Osterman
Elham Khatamzas
Michaela Barnikel
Johannes C. Hellmuth
Maximilian Münchhoff
Julia Walter
Alessandro Ghiani
Stefan Munker
Julien Dinkel
Jürgen Behr
Nikolaus Kneidinger
Katrin Milger
Publication date
01-02-2022
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-021-01669-8

Other articles of this Issue 1/2022

Infection 1/2022 Go to the issue